[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN01237A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01237A
IN2012DN01237A IN1237DEN2012A IN2012DN01237A IN 2012DN01237 A IN2012DN01237 A IN 2012DN01237A IN 1237DEN2012 A IN1237DEN2012 A IN 1237DEN2012A IN 2012DN01237 A IN2012DN01237 A IN 2012DN01237A
Authority
IN
India
Prior art keywords
disorders
dosage form
proliferative
production
pharmaceutical dosage
Prior art date
Application number
Other languages
English (en)
Inventor
Ramanan Vijayalakshmi
Sophie Tobias Irene
Specht Verwijs Dauntel
D Skwierczynski Raymond
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IN2012DN01237A publication Critical patent/IN2012DN01237A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
IN1237DEN2012 2009-07-31 2010-07-28 IN2012DN01237A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
PCT/US2010/002109 WO2011014248A1 (en) 2009-07-31 2010-07-28 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders

Publications (1)

Publication Number Publication Date
IN2012DN01237A true IN2012DN01237A (zh) 2015-05-15

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1237DEN2012 IN2012DN01237A (zh) 2009-07-31 2010-07-28

Country Status (30)

Country Link
US (3) US20110039826A1 (zh)
EP (1) EP2459173B1 (zh)
JP (2) JP2013500965A (zh)
KR (1) KR101762285B1 (zh)
CN (2) CN102548539A (zh)
AR (1) AR077436A1 (zh)
AU (1) AU2010276741B2 (zh)
BR (1) BR112012002265B8 (zh)
CA (1) CA2769531C (zh)
CL (1) CL2012000261A1 (zh)
CO (1) CO6612185A2 (zh)
CR (1) CR20120084A (zh)
EA (1) EA025277B1 (zh)
EC (1) ECSP12011703A (zh)
GE (1) GEP201606513B (zh)
IL (1) IL217839A (zh)
IN (1) IN2012DN01237A (zh)
JO (1) JO3434B1 (zh)
MA (1) MA33533B1 (zh)
MX (2) MX348197B (zh)
MY (1) MY174084A (zh)
NZ (1) NZ598096A (zh)
PE (1) PE20120788A1 (zh)
SG (2) SG177751A1 (zh)
TN (1) TN2012000046A1 (zh)
TW (1) TWI522357B (zh)
UA (1) UA110463C2 (zh)
UY (1) UY32822A (zh)
WO (1) WO2011014248A1 (zh)
ZA (1) ZA201200944B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
KR101741168B1 (ko) 2008-12-22 2017-05-29 밀레니엄 파머슈티컬스 인코퍼레이티드 오로라 키나아제 억제제 및 항­cd 항체의 병용
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
MXPA02001398A (es) 1999-08-11 2002-08-12 Idec Pharma Corp Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20.
WO2001072300A1 (en) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Uses of metal salts to stabilize taxane-based compositions
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
AU2006330587B2 (en) * 2005-12-23 2012-12-13 Glaxosmithkline Llc Azaindole inhibitors of aurora kinases
EP2037919A2 (en) 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
JP2009544617A (ja) * 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト ベンゾイミダゾリルピリジルエーテルの製剤
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
KR101741168B1 (ko) * 2008-12-22 2017-05-29 밀레니엄 파머슈티컬스 인코퍼레이티드 오로라 키나아제 억제제 및 항­cd 항체의 병용
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate

Also Published As

Publication number Publication date
NZ598096A (en) 2014-05-30
PE20120788A1 (es) 2012-07-22
CA2769531A1 (en) 2011-02-03
CO6612185A2 (es) 2013-02-01
KR101762285B1 (ko) 2017-07-28
TWI522357B (zh) 2016-02-21
AU2010276741B2 (en) 2016-07-14
EA201270205A1 (ru) 2012-07-30
US20140073630A1 (en) 2014-03-13
UY32822A (es) 2011-01-31
US9504693B2 (en) 2016-11-29
JO3434B1 (ar) 2019-10-20
TN2012000046A1 (en) 2013-09-19
US9127011B2 (en) 2015-09-08
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
ECSP12011703A (es) 2012-03-30
CN102548539A (zh) 2012-07-04
IL217839A (en) 2017-01-31
JP6014695B2 (ja) 2016-10-25
AU2010276741A1 (en) 2012-03-01
BR112012002265B8 (pt) 2021-05-25
MY174084A (en) 2020-03-09
MX348197B (es) 2017-06-05
CL2012000261A1 (es) 2012-08-03
MX2012001196A (es) 2012-03-14
WO2011014248A1 (en) 2011-02-03
JP2013500965A (ja) 2013-01-10
SG177751A1 (en) 2012-02-28
BR112012002265A2 (pt) 2016-06-14
GEP201606513B (en) 2016-07-25
AR077436A1 (es) 2011-08-24
UA110463C2 (ru) 2016-01-12
US20110039826A1 (en) 2011-02-17
CR20120084A (es) 2012-06-01
US20160158244A1 (en) 2016-06-09
TW201107331A (en) 2011-03-01
KR20120053008A (ko) 2012-05-24
CA2769531C (en) 2017-11-07
MA33533B1 (fr) 2012-08-01
EA025277B1 (ru) 2016-12-30
CN103893186A (zh) 2014-07-02
EP2459173B1 (en) 2018-02-28
ZA201200944B (en) 2015-07-29
SG10201404483VA (en) 2014-10-30
JP2015091877A (ja) 2015-05-14
EP2459173A1 (en) 2012-06-06
IL217839A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IN2012DN01237A (zh)
MX2013012588A (es) Inhibidores de cinasa.
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
NZ608116A (en) Triazine-oxadiazoles
IN2014MN00988A (zh)
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
IN2012DN03042A (zh)
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2013006768A (es) Moduladores de receptor de glucagon.
EA024038B9 (ru) Производные нитрила, их использование в фармацевтических целях и в композициях
IN2013DN02555A (zh)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.
GEP20125640B (en) Phenanthrenone compounds, compositions containing them and use thereof